Inozyme Pharma Inc (NASDAQ:INZY)’s traded shares stood at 0.6 million during the last session, with the company’s beta value hitting 1.38. At the close of trading, the stock’s price was $2.57, to imply an increase of 3.63% or $0.09 in intraday trading. The INZY share’s 52-week high remains $7.80, putting it -203.5% down since that peak but still an impressive 3.89% since price per share fell to its 52-week low of $2.47. The company has a valuation of $165.10M, with an average of 1.02 million shares in intraday trading volume over the past 10 days and average of 382.39K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Inozyme Pharma Inc (INZY), translating to a mean rating of 1.00. Of 6 analyst(s) looking at the stock, 0 analyst(s) give INZY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inozyme Pharma Inc (NASDAQ:INZY) trade information
After registering a 3.63% upside in the last session, Inozyme Pharma Inc (INZY) has traded red over the past five days. The 5-day price performance for the stock is -5.17%, and -39.24% over 30 days. With these gigs, the year-to-date price performance is -39.67%. Short interest in Inozyme Pharma Inc (NASDAQ:INZY) saw shorts transact 3.31 million shares and set a 10.99 days time to cover.
The extremes give us $16 and $16 for target low and target high price respectively. As such, INZY has been trading -522.57% off suggested target high and -522.57% from its likely low.
Inozyme Pharma Inc (INZY) estimates and forecasts
Looking at statistics comparing Inozyme Pharma Inc share performance against respective industry, we note that the company has underperformed competitors. Inozyme Pharma Inc (INZY) shares are -44.49% down over the last 6 months, with its year-to-date growth rate lower than industry average at -16.06% against 17.50%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -35.73% for the past 5-year period. While 2024 is set for a -16.46% return in earnings, projections for the next 5 years are at 13.10% annually.
INZY Dividends
Inozyme Pharma Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
Inozyme Pharma Inc insiders hold 0.51% of total outstanding shares, with institutional holders owning 96.67% of the shares at 97.16% float percentage. In total, 96.67% institutions holds shares in the company, led by ADAGE CAPITAL PARTNERS GP, L.L.C. As of 2024-06-30, the company held over 5.73 million shares (or 9.2742% of shares), all amounting to roughly $25.55 million.
The next major institution holding the largest number of shares is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC with 4.49 million shares, or about 7.2765% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $20.05 million.
